ConductScience.org, home

Paper33388161

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.

Paver EC and 10 others. Pathology, 2021. Cited by 211 papers, by iCite.

Cite this record

ConductScience Library. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Papers, record 33388161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33388161

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
PubMed
Journal
Pathology
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
211
iCite
Relative citation ratio, by iCite
12
iCite
Revised in PubMed
2021-10-22
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Paver ECElizabeth C
2Cooper WAWendy A
3Colebatch AJAndrew J
4Ferguson PMPeter M
5Hill SKSean K
6Lum TTrina
7Shin JSJoo-Shik
8O'Toole SSandra
9Anderson LLyndal
10Scolyer RARichard A
11Gupta RRuta

Source PubMed

Download CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
B7-H1 AntigenMajor topic
Biomarkers, TumorMajor topic
NeoplasmsMajor topic
Carcinoma, Hepatocellular
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Carcinoma, Transitional Cell
Colorectal Neoplasms
Diagnostic Tests, Routine
Endometrial Neoplasms
Female
Head and Neck Neoplasms
Humans
Immune Checkpoint Inhibitors
Immunohistochemistry
Immunotherapy
Kidney Neoplasms
Liver Neoplasms
Male
Melanoma
Neoplasm Grading
Prognosis
Programmed Cell Death 1 Receptor
Triple Negative Breast Neoplasms

Source PubMed

Download CSV of topics

Cited by146

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 211 citations.

PMIDTitleJournalYearIn PapersSource
42972057The genomic and epigenomic evolution of colorectal cancer.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/42972057PubMed
42949705Label-free Raman spectroscopy for cancer therapy response: from methodological framework to clinical translation.Chem Soc Rev2026https://conductscience.org/library/papers/42949705PubMed
42882767Next-Generation Immunohistochemical and RNA in Situ Hybridization Assays for Renal Neoplasia: Which Biomarkers Are Ready for Prime Time?Cancers (Basel)2026https://conductscience.org/library/papers/42882767PubMed
42816549Development of functional spatial mapping of the tumour immune microenvironment (FuncO:TiME) in advanced melanomas.BJC Rep2026https://conductscience.org/library/papers/42816549PubMed
42684559Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma.Hum Cell2026https://conductscience.org/library/papers/42684559PubMed
42614979Prognostic Factors Analysis in Patients with Hepatocellular Carcinoma Receiving PD-1/PD-L1 Inhibitors.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42614979PubMed
42570161Deciphering the immune landscape of parathyroid carcinoma: implications for immunotherapeutic responsiveness.Endocrine2026https://conductscience.org/library/papers/42570161PubMed
42397400Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42397400PubMed
42218596From Tumour to Bloodstream: Advancing PD-L1 Testing With Liquid Biopsies in Non-Small Cell Lung Cancer.Cytopathology2026https://conductscience.org/library/papers/42218596PubMed
42169955PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study.J Gastrointest Oncol2026https://conductscience.org/library/papers/42169955PubMed
42122148PD-L1-Guided Chemo-Immunotherapy in Advanced Triple-Negative Breast Cancer: A Meta-Analysis of Survival Benefits and Toxicity Profiles.Cancers (Basel)2026https://conductscience.org/library/papers/42122148PubMed
42075598The Correlation Between PD-L1 Expression in Metaplastic Breast Cancer and Clinical-Pathological Features and Prognosis.Medicina (Kaunas)2026https://conductscience.org/library/papers/42075598PubMed
42003937Comprehensive treatment for intracranial invasive sinonasal intestinal-type adenocarcinoma with a focus on radiotherapy dosage and immunological combination therapy: A case report.Oncol Lett2026https://conductscience.org/library/papers/42003937PubMed
41836111The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine. What Do Pathologists in Developing Countries Need to Know and Understand?Int J Gen Med2026https://conductscience.org/library/papers/41836111PubMed
41798957Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy.Front Immunol2026https://conductscience.org/library/papers/41798957PubMed
41766893A composite biomarker based on early dynamic changes in lactate dehydrogenase and PD-L1 expression enhances outcome prediction for immunochemotherapy in HER2-negative advanced gastric cancer.Front Immunol2026https://conductscience.org/library/papers/41766893PubMed
41677996The progress of biomarkers detection to lung cancer.Discov Oncol2026https://conductscience.org/library/papers/41677996PubMed
41626182Research progress on the impact and mechanisms of helicobacter pylori infection on the efficacy of immunotherapy for gastric cancer.Front Oncol2025https://conductscience.org/library/papers/41626182PubMed
41578901Immunoexpression of programmed death receptor 1 and its ligands in oral cavity squamous cell carcinoma.Med Oral Patol Oral Cir Bucal2026https://conductscience.org/library/papers/41578901PubMed
41533174Ultrasensitive biosensor based on AgNPs-functionalized perylene derivative nanosheets with enhanced electrochemiluminescence at narrow potential sweep range.Mikrochim Acta2026https://conductscience.org/library/papers/41533174PubMed

See all 146 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33388161

GET https://conductscience.org/api/papers/v1/33388161/cited_by?page=2